论文部分内容阅读
本文检测了２５例正常人和２０例白血病患者的淋巴细胞转化率（ＬＴ）、Ｅ－玫瑰花环形成率（Ｅ-ＲＦ）、白介素－２水平（ＩＬ－２）、自然杀伤细胞（ＮＫ）活性和淋巴细胞因子激活的杀伤细胞活性（ＬＡＫ），以及经ＩＬ－２／ＬＡＫ疗法治疗前后白血病患者细胞免疫功能的变化。结果表明白血病患者ＬＡＫ活性和细胞免疫功能显著低于正常人（Ｐ＜０．０ｌ）；抗ＣＤ＿３单克隆抗体（ＣＤ＿３ＭｃＡｂ）可显著增强ＬＡＫ细胞活性；经ＩＬ－２／ＬＡＫ为主的生物治疗后患者ＬＴ和Ｅ－ＲＦ明显增高（Ｐ＜０．０５）。证明ＩＬ－２／ＬＡＫ为主的生物治疗方法能够不同程度地逆转白血病患者细胞免疫功能的缺陷。
This study examined the lymphocyte transformation ratio (LT), E-rose rosette formation (E-RF), interleukin-2 (IL-2), and natural killer (NK) activity in 25 normal individuals and 20 leukemia patients. And lymphocyte factor-activated killer cell activity (LAK), and changes in cellular immune function in leukemia patients before and after treatment with IL-2/LAK therapy. The results showed that LAK activity and cellular immune function in leukemia patients were significantly lower than normal (P<0.0l); anti-CD_3 monoclonal antibody (CD_3McAb) could significantly enhance LAK cell activity; after IL-2/LAK-based biological therapy LT and E-RF were significantly higher in patients (P < 0.05). It is proved that the IL-2/LAK-based biological treatment method can reverse the defects of cellular immune function in leukemia patients to varying degrees.